Innate Pharma S.A. (FRA:IDDA)

Market Cap	145.05M -0.8%
Revenue (ttm)	12.64M -62.6%
Net Income	-46.05M
EPS	-0.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286
Average Volume	203
Open	1.490
Previous Close	1.500
Day's Range	1.470 - 1.490
52-Week Range	1.420 - 2.320
Beta	n/a
RSI	55.09
Earnings Date	Mar 26, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 174
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IDDA

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.